{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:32:04Z","timestamp":1793914324226,"version":"4.8.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significantly improving outcomes in non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy (NCIT) fails to achieve a major pathological response (MPR) in over 40% of patients. Consequently, the early identification of non-responders prior to treatment initiation remains a critical unmet clinical need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we performed single-cell RNA sequencing (scRNA-seq) on pre-treatment NSCLC tissue samples and integrated data from two public databases to identify signaling pathways associated with poor treatment response. Key findings were subsequently validated using multiplex immunofluorescence (mIF), and the predictive value of identified molecules was finally assessed in our cohort and GEO datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 83 patients, 23\/57 (40.35%) of these radiological responders failed to achieve MPR. Data analysis revealed activation of stress-related signaling pathways in cancer-associated fibroblasts (CAFs) and T cells from nMPR patients, with elevated expression of stress-related markers, including BAG3 and IFITM2. MIF confirmed that BAG3\n                      <jats:sup>+<\/jats:sup>\n                      IFITM2\n                      <jats:sup>+<\/jats:sup>\n                      CAFs and BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were spatially adjacent and significantly more abundant in nMPR patients. In our cohort and the two public databases, the BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood was significantly more abundant in the nMPR group compared to the MPR group (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.05). In the MPR group, there was no significant difference in BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood between the radiological PR and non-PR subgroups. The AUC values of BAG3\n                      <jats:sup>+<\/jats:sup>\n                      IFITM2\n                      <jats:sup>+<\/jats:sup>\n                      CAFs, BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and the BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood were 0.84 [95%CI: 0.746-0.931], 0.72 [95%CI: 0.603-0.835], and 0.87 [95%CI: 0.787-0.948], respectively. The OS and DFS of the BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood high group are significantly decreased than that of the low group (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.05). The level of BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood outperformed other two indicators in predicting non-response to NCIT. Consistent results were observed in GSE126044 and GSE135222.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The BAG3\n                      <jats:sup>+<\/jats:sup>\n                      CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1823199","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:04:56Z","timestamp":1783411496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouwenli","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09922-4","article-title":"Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET\/CT with postoperative pathology","volume":"33","author":"Cheng","year":"2023","journal-title":"Eur Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102017","article-title":"Interferon-\u03b3-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer","volume":"6","author":"Cao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14123-w","article-title":"Neoadjuvant chemoimmunotherapy increases tumor immune lymphocytes infiltration in resectable non-small cell lung cancer","volume":"30","author":"Chen","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00549-7","article-title":"The advent of immune stimulating CAFs in cancer","volume":"23","author":"Tsoumakidou","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","article-title":"Insights gained from single-cell analysis of immune cells in the tumor microenvironment","volume":"39","author":"Ren","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41420-024-01958-9","article-title":"Crosstalk between cancer-associated fibroblasts and regulated cell death in tumors: insights into apoptosis, autophagy, ferroptosis, and pyroptosis","volume":"10","author":"Chen","year":"2024","journal-title":"Cell Death Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217005","article-title":"Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression","volume":"597","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ccell.2024.08.020","article-title":"Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation","volume":"42","author":"Gao","year":"2024","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1619640114","article-title":"\u039420 IFITM2 differentially restricts X4 and R5 HIV-1","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","article-title":"Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming","volume":"21","author":"Liang","year":"2022","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1038\/ncomms9695","article-title":"BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages","volume":"6","author":"Rosati","year":"2015","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02193-3","article-title":"High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer","volume":"57","author":"Oliveira","year":"2025","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10452-4","article-title":"Non-invasive profiling of the tumour microenvironment with spatial ecotypes","volume":"654","author":"Zhang","year":"2026","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00301-w","article-title":"Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment","volume":"3","author":"Kuett","year":"2022","journal-title":"Nat Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ccell.2023.03.015","article-title":"Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma","volume":"41","author":"Gaglia","year":"2023","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.015","article-title":"Surgical outcomes with neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in resectable NSCLC","volume":"20","author":"Mitsudomi","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12383","article-title":"Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10503-8","article-title":"(18)F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study","volume":"34","author":"Yang","year":"2024","journal-title":"Eur Radiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-025-02435-0","article-title":"CD8(+) TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients","volume":"10","author":"Lin","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41389-024-00528-z","article-title":"USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway","volume":"13","author":"Li","year":"2024","journal-title":"Oncogenesis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.014","article-title":"IGF1\/IGF1R\/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis","volume":"393","author":"Xu","year":"2017","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.026","article-title":"In situ detection of programmed cell death protein 1 and programmed death ligand 1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC","volume":"20","author":"Lindberg","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:04:57Z","timestamp":1783411497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1823199"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823199","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1823199"}}